Study Comparing Zanzalintinib and Everolimus for Advanced Neuroendocrine Tumors

Inclusion Criteria

• Have a confirmed diagnosis of advanced neuroendocrine tumors (NETs) that cannot be surgically removed, originating from the pancreas or other areas.
• Have previously received treatment for NETs, depending on the tumor's location and activity.
• Show documented disease progression based on recent imaging tests (CT or MRI) within the last 12 months.
• Have measurable disease as determined by standard criteria.
• Provide a sample of tumor tissue, either from previous tests or a new biopsy if safe to do so.

Exclusion Criteria

• Have certain types of neuroendocrine cancers, such as small cell lung cancer, medullary thyroid cancer, or others listed.
• Have previously been treated with specific types of cancer drugs targeting VEGFR or mTOR.
• Have received chemotherapy or liver-targeted treatments within 4 weeks before starting the study.
• Have had systemic radionuclide therapy within 6 weeks before starting the study.
• Have had radiation therapy for bone metastases within 2 weeks, or other radiation treatments within 4 weeks before starting the study.